| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1020136644 |
| P356 | DOI | 10.1186/AR3827 |
| P932 | PMC publication ID | 3446479 |
| P698 | PubMed publication ID | 22548780 |
| P5875 | ResearchGate publication ID | 224878003 |
| P50 | author | Katja Lakota | Q82671666 |
| P2093 | author name string | Jungwha Lee | |
| John Varga | |||
| Monique Hinchcliff | |||
| Jun Wei | |||
| Michael L Whitfield | |||
| Snezna Sodin-Semrl | |||
| Mary Carns | |||
| P2860 | cites work | Adiponectin activation of AMPK disrupts leptin-mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS-3) | Q28583520 |
| Fat and beyond: the diverse biology of PPARgamma | Q29615416 | ||
| Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice | Q32085363 | ||
| Molecular subsets in the gene expression signatures of scleroderma skin | Q33354088 | ||
| PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis | Q33745028 | ||
| PPAR-γ ligands repress TGFβ-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis | Q33799182 | ||
| Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. | Q33950766 | ||
| Criteria for the classification of early systemic sclerosis. | Q34317138 | ||
| Elevated adiponectin serum levels in women with systemic autoimmune diseases | Q34475777 | ||
| Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis | Q35954579 | ||
| Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma | Q37071874 | ||
| A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity | Q37402787 | ||
| Transforming growth factor beta as a therapeutic target in systemic sclerosis | Q37428739 | ||
| Mechanisms of adiponectin regulation and use as a pharmacological target | Q37784586 | ||
| Fibrosis and immune dysregulation in systemic sclerosis | Q37791685 | ||
| PPAR-gamma: adipogenic regulator and thiazolidinedione receptor | Q41755813 | ||
| Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma | Q42459998 | ||
| Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein | Q42811136 | ||
| Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts | Q43223419 | ||
| The road from discovery to clinic: adiponectin as a biomarker of metabolic status | Q43241792 | ||
| PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis | Q45285303 | ||
| A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis | Q45889664 | ||
| Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. | Q51870089 | ||
| Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients. | Q54369365 | ||
| Adiponectin and leptin up-regulate extracellular matrix production by dermal fibroblasts | Q79818171 | ||
| Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus | Q80038527 | ||
| Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis | Q84483475 | ||
| Serum adipokine levels in patients with systemic lupus erythematosus | Q84660768 | ||
| P433 | issue | 3 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | R102 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker? | |
| P478 | volume | 14 |
| Q35623780 | A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosis |
| Q42229072 | Adiponectin Is Involved in Connective Tissue Growth Factor-Induced Proliferation, Migration and Overproduction of the Extracellular Matrix in Keloid Fibroblasts |
| Q47110057 | Adiponectin attenuates profibrotic extracellular matrix remodeling following cardiac injury by up-regulating matrix metalloproteinase 9 expression in mice |
| Q33860888 | Adiponectin is an endogenous anti-fibrotic mediator and therapeutic target. |
| Q58797878 | An orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosis |
| Q39450087 | An update on biomarker discovery and use in systemic sclerosis. |
| Q51385249 | Association between Functional CYP2D6 Polymorphisms and Susceptibility to Autoimmune Diseases: A Meta-Analysis. |
| Q38771824 | Biomarkers in Scleroderma: Progressing from Association to Clinical Utility |
| Q54776294 | Bleomycin inhibits adipogenesis and accelerates fibrosis in the subcutaneous adipose layer through TGF-β1. |
| Q33736823 | Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis |
| Q92104501 | Clinical associations of serum leptin and leptin/adiponectin ratio in systemic sclerosis |
| Q38156227 | Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development |
| Q37395851 | Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis |
| Q37227633 | Effectiveness of rosiglitazone in reducing flexion contracture in a rabbit model of arthrofibrosis with surgical capsular release: A biomechanical, histological, and genetic analysis |
| Q38708686 | Elevated Adipsin Levels are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis |
| Q47109594 | Interactions between TGF-β1, canonical WNT/β-catenin pathway and PPAR γ in radiation-induced fibrosis |
| Q54162257 | Meta-analysis of circulating adiponectin, leptin, and resistin levels in systemic sclerosis. |
| Q55490826 | Novel classification for global gene signature model for predicting severity of systemic sclerosis. |
| Q38164818 | Novel investigational agents for the treatment of scleroderma |
| Q45975840 | Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. |
| Q37227987 | Peroxisome proliferator-activated receptor-γ agonist troglitazone suppresses transforming growth factor-β1 signalling through miR-92b upregulation-inhibited Axl expression in human keloid fibroblasts in vitro |
| Q33790719 | Puerarin Protects against Cardiac Fibrosis Associated with the Inhibition of TGF-β1/Smad2-Mediated Endothelial-to-Mesenchymal Transition. |
| Q36093802 | Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis |
| Q86525178 | Risk factors for body composition abnormalities in systemic sclerosis |
| Q39671627 | Serum adipokines levels in patients with systemic sclerosis: A meta-analysis |
| Q53122357 | Serum adropin level and ENHO gene expression in systemic sclerosis. |
| Q53580852 | Serum omentin levels: A possible contribution to vascular involvement in patients with systemic sclerosis. |
| Q35899944 | The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β Signaling |
| Q38524619 | The Role of PPAR Gamma in Systemic Sclerosis |
| Q36633255 | The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy |
| Q64098913 | The role of adipokines in systemic sclerosis: a missing link? |
| Q47095125 | Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis Resolution in Scleroderma |
| Q38922023 | Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis |
| Q38141638 | What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis? |
Search more.